Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Want to see ATAI full AI Analyst Report?
ATAI Stock Chart & Stats
$4.03
-$0.11(-6.29%)
At close: 4:00 PM EST
$4.03
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$2.00 - $6.75
Previous CloseN/A
Volume1.44M
Average Volume (3M)5.04M
Market Cap
$1.49B
Enterprise Value$1.46B
Total Cash (Recent Filing)$230.77M
Total Debt (Recent Filing)$2.00M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 12, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding368,166,700
10 Day Avg. Volume5,663,783
30 Day Avg. Volume5,044,463
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue417.81
Enterprise Value/Gross Profit509.38
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$16.13Price Target Upside300.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$1.18M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Ample EquityVery low net leverage and ~ $199M of equity versus ~$265M of assets provide durable financial flexibility. For a cash-burning clinical-stage biotech this reduces near-term refinancing risk, allows continued R&D investment without immediate debt strain, and supports optionality for partnerships or deals over the next months.
Exceptionally High Gross MarginsSustained gross margins near 95% reflect the intellectual‑property driven economics typical of successful drug developers. If candidates progress to commercialization or generate royalties, these margins enable scalable operating leverage, supporting long-term profitability potential once fixed R&D and SG&A are absorbed.
Platform And Partnership ModelA platform approach with program entities and external collaborations spreads scientific and commercial risk across multiple assets. This structural model increases optionality, permits milestone/upfront funding from partners, and can accelerate development through specialized partners—advantages that persist beyond near-term market moves.
Bears Say
Very Small, Declining Revenue BaseRevenue of roughly $3.5M TTM and a recent decline indicate the company lacks material commercial cash flow. With no scalable product revenue, ongoing operating costs must be funded externally; this structural revenue weakness limits self‑funding ability and increases dependence on financing or partner milestones over the coming months.
Large And Worsening Cash BurnOperating and free cash flow deficits exceeding $100M TTM represent persistent structural burn. Worsening cash flow versus prior year implies higher near-term funding needs, elevating the likelihood of dilutive equity raises or onerous deals to sustain clinical programs and threatening continuity or scale of development efforts absent new capital.
Deep Negative Margins And Widening LossesNet margins near -190% and widening losses reflect heavy R&D and operating spend without offsetting revenue. Structurally poor profitability erodes returns on equity and increases dilution risk if cumulative losses require capital raises, complicating long‑term value creation until clinical successes materialize.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $2.00 and its highest was $6.75 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $1.49B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Atai Beckley N.V.’s earnings last quarter?
Atai Beckley N.V. released its earnings results on May 12, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.027.
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate is -0.11.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 368,166,700 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Atai Beckley N.V. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went up 2.723%.
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.13 (300.12% Upside)
$16.13 (300.12% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Atai Beckley N.V.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
ATAI Stock 12 Month Forecast
Average Price Target
$16.13
▲(300.12% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
32.34% Insiders
3.47% Mutual Funds
10.43% Other Institutional Investors
47.03% Public Companies and Individual Investors